<DOC>
	<DOCNO>NCT01768585</DOCNO>
	<brief_summary>This study investigate whether chronic heart rate reduction ivabradine ( Procoralan® , Servier , France ) affect aortic compliance endothelial function patient chronic stable coronary artery disease .</brief_summary>
	<brief_title>Study Investigate Effect Heart Rate Reduction With Ivabradine Vascular Elastic Properties Endothelial Function Patients With Stable Coronary Heart Disease</brief_title>
	<detailed_description>Experimental clinical data suggest sustain elevation heart rate contributes pathogenesis vascular disease ( 1 , 2 ) . In animal study accelerate heart rate associate signal event lead vascular oxidative stress , endothelial dysfunction acceleration atherogenesis ( 3 ) . The underlying mechanism partially understood appear correlate mechanic property reduction vascular compliance . Heart rate reduction I ( f ) -channel inhibition ivabradine ( Procoralan® , Servier , France ) attenuate oxidative stress , improve endothelial function reduces formation atherosclerotic plaque mice model lipid-induced atherosclerosis ( 1 , 4 ) . Aortic stiffness consequence arterial age vascular risk factor determinates cardiovascular mortality ( 5 ) . Heart rate depend repetitive pulsation appear induce fatigue fracture elastin lamellae central artery . As result vessel stiffen pulse wave reflection return early heart . In consequence aortic pressure rise pulsation flow extend small vessel organ ( notably brain kidney ) . Stiffening lead increase left ventricular ( LV ) load hypertrophy , decrease capacity myocardial perfusion , increase hemodynamic stress small arterial vessel . Several experimental investigation reveal interaction heart rate vascular compliance demonstrate positive association increase heart rate arterial stiffness ( 6 ) . Recent experimental data suggest heart rate reduction ivabradine ( Procoralan® , Servier , France ) significantly improve aortic distensibility cholesterol feed ApoE -/- mouse measure MRI technique ( 7 ) . While benefit pharmacological heart rate reduction vascular outcome observe animal study , prospective clinical data limit evidence determine whether chronic modulation heart rate improve vascular function compliance patient chronic stable coronary artery disease need .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<criteria>Age &gt; 18 year old Resting heart rate ≥ 70 bpm Sinus rhythm Chronic stable coronary artery disease ( CAD ) Coronary artery disease proven coronary angiography Written inform consent participate study Acute coronary syndrome CAD treat best surgical coronary bypass Stroke/TIA Resting heart rate &lt; 70 bpm Indwelling pacemaker AICD Severe valvular heart disease Any rhythm sinus SickSinusSyndrome , SA nodal block , &gt; 2nd degree atrioventricular block Untreated arterial hypertension Arterial hypotension ( &lt; 90/50mmHg ) Severe hepatic failure Heart failure ( NYHA class III IV ) Patient already treat study drug Symptomatic PAD Known diabetes mellitus Premenopausal woman Hypersensitivity ivabradine adjuvant Coexisting drug treatment Cytochrom P450 3A4inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>